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Loss-of-function mutations in MICU1 cause a brain and muscle disorder linked to primary 
alterations in mitochondrial Ca2+ signalling. 
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Abstract 
 
Mitochondrial Ca2+ uptake plays key roles in cell life and death. Physiological Ca2+ signalling 
regulates aerobic metabolism, while pathological Ca2+ overload triggers cell death. The 
process is mediated by the Ca2+ uniporter complex in the inner mitochondrial membrane, 
which includes MCU1, a Ca2+-selective ion channel and its regulator, MICU12. Here we 
report mutations of MICU1 in patients with a novel disease phenotype characterised by 
proximal myopathy, learning difficulties and a progressive extrapyramidal movement 
disorder. In fibroblasts from patients with MICU1 mutations, agonist-induced mitochondrial 
Ca2+ uptake at low cytosolic [Ca2+] was increased and cytosolic Ca2+ signals were reduced. 
Whilst resting mitochondrial membrane potential was unchanged in MICU1-deficient cells, 
the mitochondrial network was severely fragmented. While the pathophysiology of muscular 
dystrophy3 and the core myopathies4 involves abnormal mitochondrial Ca2+ handling, the 
MICU1 deficiency phenotype is caused by a primary defect in mitochondrial Ca2+ signaling, 
demonstrating the crucial role of mitochondrial Ca2+ uptake in man. 
 
Main text 
Mitochondrial Ca2+ homeostasis plays key roles in many aspects of cell physiology5. Cellular 
Ca2+ signals that mediate secretion, contraction or excitability are invariably coupled with 
mitochondrial Ca2+ uptake, which in turn modulates mitochondrial bioenergetic function5-7, 
buffers cytosolic Ca2+ signals6,8, and regulates Ca2+-mediated pathways leading to 
programmed and necrotic cell death9. The mitochondrial membrane potential (ǻȌm) drives 
Ca2+ transport through the mitochondrial Ca2+ uniporter (MCU)1. MCU is regulated by 
mitochondrial calcium uptake 1 (MICU1), which confers Ca2+ sensitivity to the pathway2,10. 
The physiological roles of the proteins involved in regulating mitochondrial calcium transport 
are only partially understood11-13, and mostly derive from silencing experiments in cell culture 
systems, sometimes with conflicting results. 
We studied a cohort of patients who presented in childhood with a distinctive clinical 
phenotype, comprising early onset proximal muscle weakness with a static course and 
moderately to grossly elevated serum creatine kinase (CK), accompanied by learning 
difficulties (Supplementary Table 1). Subsequently, subtle extrapyramidal motor signs 
appeared in 10/15 patients; this progressed over the course of several years to a debilitating 
disorder of involuntary movement, with variable features including chorea, tremor, dystonic 
posturing, and oro-facial dyskinesia. Additional variable features included ataxia, 
microcephaly, ophthalmoplegia, ptosis, optic atrophy and an axonal peripheral neuropathy, 
all of which suggest a possible mitochondrial disorder.  However, no patients had diabetes 
mellitus, deafness or cardiomyopathy, and respiratory chain enzyme analysis was normal in 
muscle biopsies of all cases tested (Supplementary Table 2).  In patient 4 cerebral MRI 
showed abnormal high signal in the globus pallidus, suggestive of mitochondrial disease.  
(Supplementary Fig. 1) 
Muscle biopsies were available in 6/15 cases. All showed myopathic features with diffuse 
variation in fibre size, increased internal and central nuclei (Fig.1a) and clusters of 
regenerating fibres (Fig.1b), without pronounced fibrosis or fatty infiltration. Necrotic fibres 
were rare except in one case (8b).  Fibre typing was preserved and frequent focal areas 
devoid of mitochondria (mini-cores) were observed in both fibre types in the 5 biopsies taken 
above 6 years of age (Fig.1c,d). 
The consanguineous structure of Family 1 suggested autosomal recessive inheritance (Fig. 
2a). We therefore performed homozygosity analysis using the Affymetrix Genome-Wide 
Human SNP Array 6.0. Genotype data were analyzed using SnpViewer (see URLs)  and 
IBDfinder software14. A single region of concordant homozygosity, shared by the affected 
individuals, was identified on chromosome 10 at position 73,825,652-78,713,115 (Fig. 2b). 
Whole exome sequencing of case 2a ( Fig. 1a) revealed only one potentially pathogenic 
variant within the homozygous region; a splice acceptor site mutation c.1078-1G>C in 
MICU1 NM_006077.3(Fig. 2c). This variant segregated with the phenotype in Family 1, and 
was not seen in 22 ethnically matched in-house exomes, nor in 372 ethnically matched 
control alleles analysed by PCR. Whole exome sequencing of two further affected 
individuals (UK10K_NM5061923 and UK10K_NM5061924, cases 8a and 8b respectively) 
was performed concurrently, as part of the UK10K project, with variants called and filtered as 
previously described15. The homozygous c.1078-1G>C variant was again found in both of 
these patients. This variant is absent from dbSNP 137, the 1000 Genomes database, the 
NHLBI exome variant server of 6500 exomes, the UK10K twins cohort and the ClinSeq 
study.  Sanger sequencing  (Supplementary Table 3) identified the same variant in a further 
6 affected individuals from 3 UK Pakistani families. In contrast, whole exome sequencing of 
two unrelated Dutch Caucasian families (cases LUMC1 & 2, UMCU1 & 2; Supplementary 
Fig.2,3), in which children presented with a proximal myopathy, elevated CK, and a 
movement disorder revealed a different homozygous mutation, affecting a splice donor site, 
c.741+1G>A  (Fig. 2c). A total of 15 patients, from 7 families were identified.  Neither the UK 
Pakistani families, nor the Caucasian Dutch families were knowingly related to each other, 
however genotype data from microsatellites flanking MICU1 suggest a common ancestral 
origin for individuals carrying each of the two variants (Supplementary Fig. 4). All variant and 
phenotype data were submitted to the MICU1 gene variant database (see URLs). 
Sequencing of cDNA (Supplementary Table 4) from patients with each of the splice site 
mutations showed intronic insertions causing frameshifts (Supplementary Fig. 5,6). The 
patient transcripts were shown by qPCR to undergo nonsense-mediated decay (Fig. 2d), 
and loss of protein was confirmed by western blot (Supplementary Fig. 7). Consistent with 
the clinical features displayed by patients, Micu1 was highly expressed in normal mouse 
muscle and brain (Supplementary Fig. 8,9). 
 
To evaluate the physiological consequences of the absence of MICU1, we analysed cellular 
and mitochondrial Ca2+ homeostasis in primary fibroblasts from two healthy individuals and 
two unrelated patients (cases 6 and 8a, see Supplementary Table 1, Supplementary Fig. 
10,11) in resting cells and following stimulation with a Ca2+-mobilising agonist (histamine, 10 
ȝM). Mitochondrial ([Ca2+]m) and cytosolic ([Ca2+]c) Ca2+ concentration was measured using 
mitochondrially targeted aequorin1 and fluo-4, respectively.  The initial rate of histamine-
induced mitochondrial Ca2+ uptake was increased in MICU1-deficient fibroblasts (Fig 3a,b), 
indicating increased mitochondrial Ca2+ load at lower [Ca2+]c, while the peak [Ca2+]m was 
unchanged (Fig 3c). The increased velocity of Ca2+ uptake was not due to differences in 
mitochondrial membrane potential (ǻȌm) (Fig. 3d) or altered endoplasmic reticulum (ER) 
Ca2+ content (Supplementary Fig. 12a). An increased rate of mitochondrial calcium uptake 
could result from an increased proximity of the mitochondrial pool to the ER, thus exposing 
the mitochondria to higher microdomains of calcium. We have therefore explored this 
proximity using immunofluorescence. The data do not reveal any significant change in ER 
mitochondrial proximity (Supplementary Fig.13). While we recognize that EM data might be 
more precise, it is important to note that changes in ER/mitochondrial contacts due to altered 
expression of related proteins can be observed in this way16,17. 
Since aequorin is not suitable for the quantification of low submicromolar [Ca2+]18, in order to 
better appreciate the relationship between cytosolic and mitochondrial [Ca2+] close to basal 
levels, we used rhod-2 loaded cells for high temporal resolution imaging, which probe has 
higher Ca2+ affinity and also allows the simultaneous measurement of [Ca2+] in both 
compartments19. Despite the limitations inherent in this assay,  resting [Ca2+]m was 
significantly higher, and the velocity of mitochondrial Ca2+ uptake was significantly increased 
in the patient derived MICU1-deficient cells (Fig 3e-j). The elevated [Ca2+]m at rest was 
confirmed by ratiometric measurements using the recombinant 2mtGCaMP6 probe (Fig. 3h). 
Plotting the mitochondrial versus cytosolic Ca2+ values revealed that MICU1 deficiency leads 
to the loss of the physiological cooperative sigmoid regulation of mitochondrial [Ca2+]7 (Fig. 
3j), resulting in an elevated basal Ca2+ load in the organelle and in rapid response to 
changing cytosolic [Ca2+]. These results were in accordance with the previously described 
function of the protein in other cell types10. In addition, the histamine-induced global peak 
[Ca2+]c in the MICU1-deficient cells was significantly reduced (Fig. 3k,l). This finding is 
consistent with increased mitochondrial Ca2+ buffering, since the effect was prevented 
following the inhibition of mitochondrial Ca2+ uptake by the uncoupler FCCP (Fig. 3m) and 
ER Ca2+ content was unchanged in the MICU1 deficient cells (see Supplementary Fig. 12a).  
Confocal imaging of mitochondria loaded with the potential-sensitive dye TMRM (Fig. 4a,b) 
or the Ca2+-sensitive probe, rhod-2 (Fig. 4c,d) revealed that a significant proportion of the 
MICU1-deficient cells showed a highly fragmented mitochondrial network. In addition, the 
intensity of the rhod-2 fluorescence in those MICU1 mutant cells that showed a fragmented 
mitochondrial network was significantly increased, suggesting that mitochondrial 
fragmentation was associated with increased resting [Ca2+]m (Fig. 4e). Moreover, re-
expression of wild type MICU1 rescued this phenotype (Fig. 4f,g; Supplementary Figs.14 
and 15).  Together, these data show that loss of MICU1 leads to the chronic activation of the 
MCU channel even at resting [Ca2+]c, and hence to Ca2+-induced fragmentation of the 
mitochondrial network.  
As raised matrix [Ca2+]m activates the tricarboxylic acid cycle18 it has also been suggested 
that MICU1 regulates Ca2+-mediated activation of mitochondrial energy metabolism through 
its role as the Ca2+ sensor of the MCU complex10. NAD(P)H autofluorescence was 
significantly increased in the MICU1 deficient cells, consistent with this model (Fig. 4h,i). 
Measurements of NAD(P)H fluorescence following histamine stimulation reveals the 
maximal [Ca2+]m mediated change in energy metabolism20. This was not significantly 
different between the control and MICU1 deficient patient cells (Fig. 4i), consistent with the 
aequorin measurements of peak histamine stimulated [Ca2+]m (see Fig 3a,c). The small but 
significant increase in NAD(P)H following histamine stimulation of MICU1 deficient patient 
cells (Fig. 4i) shows that the increase in resting [Ca2+]m in these cells was not sufficient to 
saturate the Ca2+ dependent metabolic pathway. No significant differences could be 
detected in either basal or histamine-induced mitochondrial O2 consumption, nor in 
respiratory control or respiratory reserve capacity in control and MICU1-deficient fibroblasts, 
(Fig. 4j,k), in keeping with the unchanged ǻȌm (see Fig. 3d).  
These data show that loss of MICU1 results in a complex cellular phenotype due to 
increased mitochondrial Ca2+ load, already at basal cytoplasmic [Ca2+] or following 
spontaneous, low frequency cytoplasmic Ca2+ transients (see Supplementary Fig. 12b-e). 
The reduction in cytoplasmic Ca2+ signals as a result of enhanced mitochondrial Ca2+ 
buffering could disturb Ca2+-dependent processes such as muscle contraction or synaptic 
transmission. Furthermore, the chronic activation of the MCU channel and subsequent 
chronic elevation of the mitochondrial matrix Ca2+ load may lead to moderate mitochondrial 
stress, as reflected by the fragmented phenotype seen in a proportion of cells. However, at 
least under resting conditions, the fibroblasts appear to compensate for the stress-induced 
dysfunction, without apparent defects in overall cellular metabolic function. The slow 
progression of the clinical features in affected patients appears to be consistent with 
limitations of these compensatory mechanisms in vivo in the long term. 
The dysfunction of mitochondrial Ca2+ uptake described in these patients results in a novel 
phenotype, the clinical and pathological features of which overlap with those of muscular 
dystrophies, congenital core myopathies and mitochondrial myopathies. Mitochondrial 
damage and dysfunction are features common to these disorders. In Duchenne muscular 
dystrophy, sarcolemmal damage leads to dysregulation of cellular Ca2+ homeostasis, and 
mitochondrial Ca2+ overload-induced necrosis of myocytes3. In Ullrich congenital muscular 
dystrophy, the deficiency of collagen VI causes defects in mitochondrial architecture, Ca2+ 
dysregulation, and cell death21.  In core myopathies, mutations in the type 1 ryanodine 
receptor (RYR1) gene lead to Ca2+ leak from the sarcoplasmic reticulum (SR) and 
consequent muscle dysfunction4. In these diseases, early pathological changes affect 
confined areas of muscle fibres. Within these, initial mitochondrial or SR disruption causes 
loss of local Ca2+ sequestration, causing mitochondrial swelling and disruption, and 
eventually complete loss of mitochondria from the cores4.  
The increased velocity of mitochondrial Ca2+ uptake and resting mitochondrial Ca2+ loading 
that we have seen in patients with MICU1-deficiency defines a new mechanism underlying 
neuromuscular disease; a primary defect in mitochondrial Ca2+uptake. The phenotype 
described provides a much-needed in vivo insight into the biological role of this regulator of 
mitochondrial Ca2+ signalling. 
 
 
URLs 
http://sourceforge.net/projects/snpviewer/ 
http://www.LOVD.nl/MICU1 
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FIGURE LEGENDS 
 
Figure 1. Quadriceps biopsies from affected individuals. (a) Haematoxylin and eosin 
stained section from the biopsy of patient 4 at 7.3 years showing a mild excess of internal, 
and central nuclei in type I fibres. (b) A cluster of basophilic regenerating fibres with 
prominent vesicular nuclei in the biopsy from patient 3a at 3.3 years. These fibres label 
strongly for developmental myosin (b, inset), a marker of regeneration. (c,d). Sections 
stained for NADH-TR from the biopsies of patient 3a at 3.3 years (c) and patient no. 8b at 
10.7 years(d) showing good fibre typing and areas devoid of stain in fibres of both intensity 
(minicore-like areas).  Scale bar 50 ȝm. 
 
Figure 2. Mutations in MICU1 were identified in a multiplex consanguineous family. 
Pedigree of a consanguineous family with four affected children (a). A region of 
homozygosity shared between affected individuals V:1, V:4 and V:5 in the pedigree (a) is 
displayed using SNPviewer and is situated on chromosome 10 between 73.8 – 78.7 Mb (b).  
Variants identified from whole exome sequencing were confirmed by Sanger sequencing 
and annotated on the MICU1 transcript (c).  qPCR showed significant loss of MICU1 
messenger RNA in patients with both mutations.  Bar chart shows mean values +/- SEM 
from three replicates.  One-way ANOVA was used with post-hoc Bonferoni tests between 
each sample. *** < 0.001 (d). 
 
Figure 3. Loss of MICU1 leads to increased mitochondrial Ca2+ load and reduced 
cytoplasmic Ca2+ transients without altering ǻȌm. Histamine induced mitochondrial (a-j) 
and cytoplasmic (k-m) Ca2+ signals were measured in primary fibroblasts from age matched 
healthy individuals (controls) and two patients carrying MICU1 mutations (ǻMICU1 8a and 
6). For [Ca2+]m measurements cells were transduced with an adenoviral mtAEQwt vector (a-
c) and luminescence of cell populations were measured or cells were loaded with rhod-2 AM 
and mitochondrial regions of interest (ROI) were analysed by imaging (e-j) as described in 
the Online Methods (scale bar 10 ȝm). Basal [Ca2+]m was further assessed by imaging 
2mtGCaMP6 expressing cells (h). [Ca2+]c was measured either in cytoplasmic ROIs in rhod-
2 AM loaded cells or in a population of fluo-4 loaded cells using fluorimetry as described in 
Supplementary Methods. Cytoplasmic and mitochondrial rhod-2 intensity traces  (f,g) were 
obtained from nuclear (where mitochondrial buffering of Ca2+ does not occur) and 
mitochondrial ROIs, respectively, as indicated in e. The rate of mitochondrial Ca2+ uptake (b, 
i) was quantified by calculating the time taken to reach half of the peak values (c, f, g). The 
aequorin and fluo-4 signals were calibrated into [Ca2+] values, as described in 
Supplementary Methods. Steady state intensity of TMRM was measured using confocal 
microscopy (d). a and c show representative traces, bar charts and f, g, j show mean ± SEM 
from >9 traces from 3 separate experiments. For pairwise comparisons of means (i) t-test, 
otherwise one-way ANOVA was used with post-hoc Bonferoni tests between each sample. * 
p < 0.05. 
 
Figure 4. The effect of MICU1 loss on mitochondrial morphology, basal [Ca2+]m and 
mitochondrial energy metabolism. Primary fibroblasts from age matched healthy 
individuals (controls) and two patients carrying MICU1 mutations (ǻMICU1 8a and 6) were 
loaded with fluo-4-AM to visualise cell boundaries (green) and either TMRM (a, b) or the 
Ca2+ sensitive dye rhod-2-AM (c, d), accumulating in mitochondria due to their positive 
charge (grey scale). Cells (>100/sample from at least 3 separate experiments) were scored 
according to the morphology of their mitochondrial network, and the percentage of cells with 
a fragmented network is shown (a, c). b and d middle panels show magnification of 
mitochondrial networks (scale bar 20 ȝm). e, the intensity of rhod-2 was quantified in control 
and MICU1 mutant cells and grouped according to mitochondrial morphology, following 
background subtraction and thresholding of confocal images (see Supplementary Methods). 
In f, g MICU1 was expressed in control and ǻMICU1 (8a and 6) cells using an adenoviral 
construct which also expressed GFP. TMRM (f) and rhod-2 (g) loaded cells were imaged 
using a high content imaging system (ImageXpress, see Supplementary Methods) and GFP 
positive and negative cells were analysed for morphology (f) or basal mitochondrial [Ca2+] 
(g). Details of the morphology scoring and normalisation of the rhod-2 signal is described in 
Supplementary Figs. 14 and 13, respectively, see also Supplementary Methods. In panel h, i 
NAD(P)H fluorescence was imaged using UV confocal microscopy in resting and histamine 
(10 ȝM) stimulated cells (scale bar 10 ȝm). j, Oxygen consumption of intact control and 
MICU1 mutant fibroblasts was measured in suspension using high resolution respirometry 
(see Supplementary Methods). Basal, leak (in the presence of 2.5 ȝM oligomycin) and 
maximal respiration (in the presence of 1 ȝM FCCP) are shown. Panel k shows the effect of 
histamine (10 ȝM) on basal respiration, measured 1 min after the addition of the agonist. 
The number of images and cells analysed in f, g are described in the Supplementary 
Methods. For pairwise comparison of means t-test (k), otherwise one-way ANOVA was used 
with post-hoc Bonferoni tests between each sample Bar charts show mean ± SEM values 
from 3 separate experiments. * p < 0.05. 
 
 
ONLINE METHODS 
 
Research subjects 
All families provided written informed consent, and this study was approved by the boards of 
the Leeds East and Great Ormond Street Hospital Research Ethics Committees (Refs Leeds 
East 07/H1306/113 and GOSH 00/5802 respectively) and the institutional review board of 
the University of Leiden. Patients were recruited from the muscle clinics of the above 
institutions. We used standard methods to isolate genomic DNA from peripheral blood of the 
affected children and family members or from frozen fetal tissue or amniocytes. 
Chromosome analysis was performed for at least one affected individual of each family. 
 
Histology, histochemistry and immunohistochemistry 
All histological and histochemical studies, H&E, NADH, SDH and COX, were performed on 
frozen sections (10 µm)22. Immunohistochemical studies were performed at the room 
temperature. Briefly, unfixed frozen serial sections (7 µm) were incubated with primary 
antibodies (foetal/neonatal myosin, mouse monoclonal WB-MHCn (Abcam, ab49461), 1:15, 
and embryonic myosin, mouse monoclonal Rnmy/9D2 , 1:20, (Leica,Novacastra,  NCL-
MHCd) for 1 hour followed by three washes in phosphate buffered saline (PBS) at pH 7.2. 
The sections were then incubated with the appropriate biotinylated secondary antibodies 
(GE Healthcare Life Sciences, RPN1001) for 30 minutes followed by streptavidin peroxidase 
HRP 1:150 for 30 minutes. After washes, the sections were developed with 3,3-
diaminobenzidine for 10 minutes.  
 
SNP genotyping and data / variant annotation.  
Birdseed genotype files generated by the Affymetrix Genotyping ConsoleTM were analysed 
using SnpViewer (see URLs) to identify concordant regions of homozygosity. A single 
homozygous region shared between affected individuals was found between 
RS1668169;RS10824473 on chr10:73,825,652-78,713,115 containing 42 RefSeq genes; 
457 non-redundant RefSeq coding exons (76.4 kb). 
 
Whole exome sequencing  
Alignment and variant calling:  
Target capture was performed using the Agilent SureSelect All Exon v4 exome enrichment 
kit according to standard manufacturer protocols.  Sequencing of 80 bp reads was 
performed using an Illumina GAIIx.  Reads were aligned to GRCh37 using novoalign 
(Novocraft Technologies, Selangor, Malaysia) and processed using the Genome Analysis 
Toolkit (GATK)23 and Picard (see URLs) to perform indel realignment and duplicate removal.  
SNV and indel variants were called using the UnifiedGenotyper feature of the GATK.  
Filtering: 
Bespoke perl scripts were used to remove variants present in dbSNP129 or with a minor 
allele frequency  1 % in dbSNP132 and to annotate functional consequences. Variants 
present in another 22 in-house exomes were also removed. Of the RefSeq coding bases 
within the autozygous region identified in family 1, 91.9 % were covered by at least 5 good 
quality reads (minimum phred-like base quality 17 and minimum mapping quality of 20). 
We selected for variants causing indels within coding regions, non-synonymous SNVs or 
alteration of splice consensus sequences. Following the filtering described above, three such 
variants were identified in the autozygous region identified in family 1, comprising two 
missense SNVs in DUSP13 (NM_001007273: c.223A>G,p.S75G and c.746G>A,p.C249Y) 
and alteration of the invariant splice acceptor site in MICU1. Both missenses were predicted 
benign by Polyphen, SIFT and Condel and had a global MAF greater than 30 % in 1000 
genomes data leaving the splice site mutation in MICU1 as the only likely pathogenic variant 
(NM_001195518: c.1078-1G>C). 
 
Mutation analysis 
Primers were designed for all coding exons of MICU1 using Primer3 (supplementary table 
2)24. Direct sequencing was performed using the dideoxy chain termination method (ABI 
“BigDye 3.0” system) on an ABI 3730 DNA sequencer, and sequences analyzed using 
4Peaks software. 
 
Gene expression analyses with quantitative real-time PCR. 
MICU1 expression in patient and control fibroblasts was analysed with quantitative real-time 
PCR. Total RNA was converted to cDNA using the Superscript III first-strand cDNA system 
(Life Technologies). PCR analysis of cDNA was performed using PAGE-purified primers 
specific for human MICU1(Sigma-Aldrich), after optimization to eliminate primer-dimers and 
subsequent confirmation by analysis of amplimer dissociation curves after a quantitative 
PCR run. Each reaction was run in triplicate. Amplimer levels were quantified continuously 
with the SYBR GreenER qPCR system (Invitrogen) using an ABI 7500 instrument, 
essentially as described previously25. 36B4 cDNA was amplified for normalization. 
 
Cell culture 
Skin biopsies were taken from patients after obtaining informed patient consent. Control skin 
samples were obtained from paediatric patients (undergoing surgical procedures) with no 
known neuromuscular disease following written informed research consent. Fibroblasts were 
grown from skin explants and cultured in Dulbecco’s modified Eagles medium (Invitrogen) 
supplemented with 20% foetal bovine serum (Invitrogen), 1% L-glutamine (Sigma) and 1% 
penicillin, streptomycin and neomycin (Sigma) at 37 °C in 5% CO2. Patient cell-lines were 
confirmed to be harbouring the correct, homozygous mutation in MICU1 by Sanger 
sequencing prior to functional studies.  Cell lines were routinely tested for mycoplasma 
contamination. 
MICU1 expression and western blotting  
The adenovirus expressing MICU1-HA and GFP were created using the AdEasy strategy 
(Stratagene). Adenoviral vectors contain two distinct promoters that independently drive the 
expression of the gene of interest and of GFP. Therefore mock plasmid expresses only GFP 
protein. Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen), 
supplemented with 10% fetal bovine serum (FBS) (Invitrogen) and infected with the different 
adenoviruses at a MOI (multiplicity of infection) of 50 pfu/cell.  
After 48 hours of expression cells were lysed in RIPA lysis buffer (1% Triton X-100, 0.1% 
SDS, 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% Sodium Deoxycholate, 1 mM EDTA and 
Complete EDTA-free protease inhibitor mixture (Roche Applied Science) and quantified with 
the BCA method (Pierce). 40 ȝg of total proteins were separated by SDS-PAGE gel 
electrophoresis, transferred to Hybond-C Extra membrane (Amersham) and stained with 
Ponceau S solution. MICU1-HA was visualised with a polyclonal α-HA antibody (Sigma). All 
the antibodies were used at a dilution of 1:1000 and were from Sigma (MCU - hpa016480; 
MICU1 - hpa037480) or Santa Cruz ( -TOM20). Secondary, HRP-conjugated antibodies 
(1:5000) were from BioRad (170-6515 and 170-6516). 
 
Immunofluorescence and analysis of ER-mitochondrial co-localisation 
Control and MICU1 mutant cells were plated on glass coverslips and either left untreated or 
were treated with 1 ȝM thapsigargin for 24h. Cells were fixed in 4% paraformaldehyde (20 
min, RT), washed in PBS (5min) and blocked in PBS containing 1% BSA and 1% FBS (1h, 
RT). Primary antibodies (grp75, sc-1058, Santa Cruz; PDI-A3, hpa003230, Sigma) were 
used at 1:200 dilution (O/N 4ºC). For visualisation of grp-75 (mitochondria) and PDIA3 (ER) 
the appropriate Alexa488 and 594 conjugated secondary antibodies were used, respectively 
(1h, RT, 1:200, Invitrogen). Cells were imaged using a Zeiss 700 CLSM confocal system, 
with 488 and 535nm lasers for excitation, emission settings for optimal separation, 
calculated by the Zeiss ZEN acquisition software, and 63x/1.4NA/oil objective. Z-series of 
images were acquired using <1AU pinhole diameter and <400nm distance between Z-
planes. Settings for the acquisition and thresholding were kept standard for the whole 
experimental set. Co-localisation of the red and green signals was quantified the JACoP v2.0 
plugin (http://rsbweb.nih.gov/ij/plugins/track/jacop.html)26 in ImageJ. Mander’s coefficients of 
the two signals to estimate of the amount of co-localizing signal from a channel over another 
were calculated and shown. To visualise co-localizing pixels the resulting Costes overlay 
images were used.  
 
Live cell confocal imaging of mitochondrial membrane potential and NAD(P)H 
Confocal imaging was used to measure mitochondrial membrane potential, mitochondrial 
resting Ca2+ content, NAD(P)H redox state and to assay mitochondrial morphology. For all 
imaging experiments cells were grown on 22mm glass coverslips or 35mm imaging dishes 
(WPI). Measurements were carried out in recording buffer (RB [in mM]: NaCl 138, KCl 5.6, 
NaHCO3 4.2, NaH2PO4 1.2, MgCl2 1.2, CaCl2 2.6, D-glucose 10, HEPES 10). All images 
were acquired on a Zeiss 700 CLSM or a Zeiss 510 UV-VIS CLSM. For measurements of 
mitochondrial membrane potential cells were equilibrated with tetramethyl rhodamine methyl 
ester (TMRM, 25nM, 30 min, 37ºC) before placing on the heated stage of the CLSM and 
images were acquired using a 63x/1.4 NA/oil objective. The dye was present throughout 
imaging. Fluorescence was excited at 535nm and measured at >560nm. Z stacks were 
acquired and maximal projections were used for quantification to avoid a bias in the focal 
plane. NAD(P)H imaging was carried out using the Zeiss 510 UV-VIS CLSM with the pinhole 
wide open to maximise signal. Fluorescence was excited using the 351nm line of an Argon 
laser and measured between 435 and 485 nm. ImageJ or the Zeiss Zen analysis software 
were used for image analysis. Images were thresholded to quantify the mean of 
mitochondrial localised signal intensities. Identical acquisition settings and threshold values 
were used throughout the set of experiments. 
 
Mitochondrial and cytosolic Ca2+ measurements 
Mitochondrial [Ca2+] measurements with aequorin 
Dynamic mitochondrial [Ca2+] measurements were performed in cells transduced with the 
mitochondrial targeted luminescent aequorin probe mtAEQ, encoded by an adenoviral 
construct as previously described1. Cells were seeded in 96 well plates (50,000/well) and 
histamine (10 ȝM) induced mitochondrial signals were measured in a luminescence plate 
reader (Fluostar Optima, BMG Labtech, UK) using 3mm luminescence optics and light guide 
after 48h of viral transduction. Prior to measurements cells were reconstituted with 
coelenterazine (Invitrogen) for 2h at 37ºC and luminescence values converted into [Ca2+] as 
previously described (Traba et al. PMID 22015608).  
 
Mitochondrial [Ca2+] measurements with rhod-2 
Measurements of resting mitochondrial [Ca2+] were made using cells loaded with 5ȝM rhod-2 
AM for 30 min at R.T. prior to washing and confocal imaging (ex=535nm em>560nm, Zeiss 
700 CLSM). Images were background corrected by subtracting mean pixel values of a cell-
free ROI. Dynamic mitochondrial [Ca2+] measurements were carried out on cells loaded with 
5ȝM rhod-2 AM for 20 min at R.T., followed by 10 min incubation at 37ºC. For imaging an 
Olympus IX71 inverted epifluorescence microscope (Olympus) fitted with a computer 
controlled motorised stage (Applied Scientific Instrumentation) with a 40x fluorite objective 
lens (N.A. 0.6/air) and a full-enclosure environmental chamber heated to 37°C (Digital Pixel 
Imaging, Brighton, UK). Images were collected using a Hamamatsu C10600-10B CCD 
camera (Hamamatsu Corporation), and recorded using MetaFluor 7.8 (Universal Imaging). 
Illumination was provided by light from a metal halide arc lamp passing through a computer 
controlled filter wheel (Prior Scientific) and a 84000v2 Quad filter set (Chroma Technology), 
using a D-350/50x excitation filter. To achieve high temporal resolution 50ms acquisition 
time were used and streamed into the computers RAM, and images were saved following a 
run of approximately 1 min. Images were analysed using MetaFluor Analyst. Nuclear 
(representing cytosolic values without mitochondrial buffering) and mitochondrial regions 
were measured from each cell, following background correction by subtracting mean pixel 
values of a cell-free ROI in each frame. Fluorescence intensity values were normalised to 
the initial cytosolic values. 
 
Mitochondrial [Ca2+] measurements with 2mtGCaMP6m 
In order to test resting [Ca2+]m with high sensitivity, we developed a new calcium probe 
based on the last generation GCaMP probe27 targeted to the mitochondrial matrix. We chose 
the GCaMP6m version, due to its highest calcium affinity, with its Kd (167 nM) in the range of 
normal resting [Ca2+]m. 2mtGCaMP6m was obtained by the addition of 2 tandem 
mitochondrial targeting sequences (derived from COX8A of human origin) to the GCaMP6m 
sequence (Addgene plasmid 40754) and was created by custom gene synthesis (Life 
Technologies). In order to be independent of basal fluorescent intensity variations due to the 
variable expression levels of the probe, we took advantage of the isosbestic point in 
GCaMP6m excitation spectrum: we experimentally determined in living cells that exciting 
GCaMP6m at 410 nm leads to fluorescence emission which is not Ca2+-dependent. As a 
consequence, the ratio between 474 and 410 nm excitation wavelengths is proportional to 
[Ca2+] while independent on probe expression levels. Fibroblasts were grown on 24 mm 
coverslip and transfected with 2mtGCaMP6m encoding plasmid using Lipofectamine LTX 
according to manufacturer’s instruction (Life Technologies). After 36 hours, coverslips were 
placed in 1 mL of KRB buffer and imaging was performed on a Zeiss Axiovert 200 
microscope equipped with a 63x/1.4 N.A. PlanApochromat objective. Excitation was 
performed with a Deltaram V high speed monochromator (Photon Technology International) 
equipped with a 75W Xenon Arc lamp. Images were captured with a high sensitivity Evolve 
512 Delta EMCCD (Photometrics). The system is controlled by Metamorph 7.5 and was 
assembled by Crisel Instruments. Cells were thus alternatively illuminated at 474 and 410 
nm and fluorescence was collected through a 515/30 nm bandpass filter (Semrock). 
Exposure time was set to 300 ms. At least 5 fields were collected per coverslip, and each 
field was acquire for 20 s (0.5 frame/s). Analysis were performed with the Fiji distribution of 
ImageJ28. Both images were background corrected frame by frame by subtracting mean 
pixel values of a cell-free ROI. Data are presented as the mean ± S.E.M. of the averaged 
ratio of all time points.  
 
Cytosolic [Ca2+] measurements with fluo-4 
Dynamic cytoplasmic [Ca2+] measurements were performed in the same plate reader 
(Fluostar Optima, BMG Labtech, UK, see aequorin measurements) using fluorescence 
optics and light guide with 485BP12 excitation and Em520 emission filters in fluo-4-AM 
loaded (30 min R.T.) cells. To avoid leakage of the dye, RB was supplemented with 1 mM 
probenecid (Sigma). Calibration of the background (measured in an empty well with RB) 
corrected fluorescence intensities into [Ca2+] was done using the following equation29:  
[Ca2+] = Kd x (F/Fmax – 1/Rf)/(1 - F/Fmax) 
where Kd = 350nM, Fmax = maximum fluorescence after ionomycin application, Rf = 100 
 
High content imaging of mitochondrial morphology and basal mitochondrial [Ca2+] 
Control and ǻMICU (8a and 6) cells expressing MICU1 and GFP were imaged using 
the ImageXpress Micro XL high content imaging system (Molecular Devices). Cells were 
seeded in 96 well thin bottom plates (BD Biosciences) and loaded in RB with either TMRM 
(25 nM, present during the whole experiments) or rhod-2 AM (5 ȝM, 20 min RT, followed by 
30 min incubation in dye-free RB) and 1 ȝg/mL Hoechst 33342 (present during the 
experiment) to label nuclei for cell counting. Cells were imaged using a custom protocol to 
image 3 wavelengths (Lumencor solid sate illumination with Semrock [Brightline] filters (nm) 
ex377/50 em447/60 for Hoechst 33342; ex472/30 em520/35 nm for GFP ex531/40 
em593/40 for TMRM and rhod-2), nine fields/well with a Nikon 40X Plan Apo NA 0.95 dry 
objective, binning 1 with a CMOS detector. Acquisition and analysis were performed using 
MetaXpress software. The workflow of quantification and morphology scoring are described 
in Supplementary Figure S11 and S12, respectively.  
  
Oxygen consumption measurements 
Cells were trypsinised and resuspended in HEPES (20 mM) buffered DMEM supplemented 
with 5.5 mM glucose, 2 mM glutamine and 1 mM pyruvate at 1 million cells/ml. Respiration 
rates were measured at 37ºC with the High Resolution Oxygraph (Oroboros Oxygraph-2k, 
Graz, Austria). Maximal oxidative capacities were determined in the presence of carbonyl 
cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP, 1 ȝM), state 4 respiration values were 
obtained in the presence of oligomycin (2.5 ȝM), non-mitochondrial (background) oxygen 
consumption was determined in the presence of Antimycin-A (2.5 ȝM). 
 
Statistics 
Sample sizes for functional measurements (listed in the legends of Figs. 3 and 4) were 
determined to achieve a statistical power of 0.95 using the G*Power 3.1.3 for Mac30, 
depending on the required effect size which was considered biologically considerable. 
Where standard deviations exceeded the estimated value, sample sizes were increased. 
These calculations assumed normal distribution of the samples, two sided one-way ANOVA 
or t-test to compare difference between means of two independent groups. Mean ± SEM 
values are shown on all figures. F-tests showed equal variance for all tests. 
  
URLs  
SnpViewer: http://sourceforge.net/projects/snpviewer/ 
Picard tools: http://picard.sourceforge.net/ 
Image J: http://rsbweb.nih.gov/ij/ 
Primer 3: http://bioinfo.ut.ee/primer3-0.4.0/ 
 
 
 
 
References  
ͳ ǡǤǡǡǤǡǡǤǡǡǤƬǡǤǦ
ǤNature
476ǡ͵͵͸Ǧ͵ͶͲȋʹͲͳͳȌǤ
ʹ ǡ	Ǥ et al.ͳ	
ȋʹΪȌǤNature467ǡʹͻͳǦʹͻ͸ȋʹͲͳͲȌǤ
͵ ǡǤǤ et al.
Ǧ
ǤNat Med14ǡͶͶʹǦͶͶ͹
ȋʹͲͲͺȌǤ
Ͷ ǡǤ et al.
ǤProc Natl Acad Sci U S A106ǡʹͳͻͻ͸Ǧ
ʹʹͲͲͳȋʹͲͲͻȌǤ
ͷ ǡǤǤƬǡ
ǤǤEssays 
Biochem47ǡͳͳͷǦͳ͵͹ȋʹͲͳͲȌǤ
͸ ǡǤ
ǤǡǡǤǤƬǡǤǤ
ǤPhysiol Rev70ǡ͵ͻͳǦ
ͶʹͷȋͳͻͻͲȌǤ
͹ ǡ
ǤƬǡǤǤǣʹΪǤ
Physiology (Bethesda)23ǡͺͶǦͻͶȋʹͲͲͺȌǤ
ͺ ǡǤƬǡǤʹΪǣ
ǤPhysiol Rev86ǡ͵͸ͻǦͶͲͺȋʹͲͲ͸ȌǤ
ͻ 
ǡǤǡǡǤǡǡǤƬǡǤʹΪ
ǤCell Death Differ14ǡͳʹ͸͹Ǧͳʹ͹ͶȋʹͲͲ͹ȌǤ
ͳͲ ǡ
Ǥ et al.ͳ
ȋʹΪȌǤCell Metab17ǡͻ͹͸Ǧͻͺ͹ȋʹͲͳ͵ȌǤ
ͳͳ ǡǤ et al.ʹǡͳǡ
ǤPLoS One8ǡͷͷ͹ͺͷȋʹͲͳ͵ȌǤ
ͳʹ ǡǤ et al.ͳǦ
ȋʹΪȌǤCell151ǡ͸͵ͲǦ͸ͶͶ
ȋʹͲͳʹȌǤ
ͳ͵ ǡǤǤ et al.
ǤNature476ǡ͵ͶͳǦ͵ͶͷȋʹͲͳͳȌǤ
ͳͶ ǡǤǤǡǡǤǡǡǤǤǡǡǤ	ǤƬǡǤǤ
ǣǦ
ǤHum Mutat
30ȋʹͲͲͻȌǤ
ͳͷ ǡǤ et al.͵
ʹ
ǦǤAm J Hum Genet92ǡ͵ͷͶǦ͵͸ͷ
ȋʹͲͳ͵ȌǤ
ͳ͸ ǡǤ et al.ʹȋȌǦ
ʹΪǦǤProc Natl Acad Sci U S A108ǡ
ȋʹͲͳͳȌǤ
ͳ͹ ǡǤ et al.ͳ
ǤMolecular cell32ǡ͸ͶͳǦ͸ͷͳ
ȋʹͲͲͺȌǤ
ͳͺ ǡǤǡǡǤǡǡǤǡǡ
ǤƬǡǤ
ǣǤBiochim 
Biophys Acta1742ǡͳͳͻǦͳ͵ͳȋʹͲͲͶȌǤ
ͳͻ 
ǡǤǤƬǦǡǤǡǦ
ʹΪǤCell calcium30ǡ͵ͳͳǦ͵ʹͳȋʹͲͲͳȌǤ
ʹͲ ǡǤƬǡǤ
ǤʹΪ
ǤMolecular and cellular endocrinology215ǡ
ͳͳͷǦͳͳͺȋʹͲͲͶȌǤ
ʹͳ ǡǤǤ et al.
ǤNat Genet35ǡ͵͸͹Ǧ͵͹ͳȋʹͲͲ͵ȌǤ
ʹʹ ǡǤǡǡǤǤƬǡǤMuscle biopsy : a practical approachǤͶ
ǡȋǡʹͲͳ͵ȌǤ
ʹ͵ ǡǤ et al.
ǣ
ǦǤGenome research20ǡͳʹͻ͹Ǧ
ͳ͵Ͳ͵ȋʹͲͳͲȌǤ
ʹͶ ǡǤƬǡǤ͵
ǤMethods Mol Biol132ǡ͵͸ͷǦ͵ͺ͸ȋʹͲͲͲȌǤ
ʹͷ ǡǤǤ et al.Ǧ
ͳ
ǤHum Mol Genet16ǡͳ͹͵Ǧ
ͳͺ͸ȋʹͲͲ͹ȌǤ
ʹ͸ ǡǤƬǡ	ǤǤ
ǤJournal of microscopy224ǡʹͳ͵Ǧʹ͵ʹȋʹͲͲ͸ȌǤ
ʹ͹ ǡǤǤ et al.
ǤNature499ȋʹͲͳ͵ȌǤ
ʹͺ ǡǤ et al.	ǣǦǦǤ
Nature methods9ȋʹͲͳʹȌǤ
ʹͻ ǡǤǡǡǤ	ǤǡǡǤǤƬǡǤ
ǤBiophysical 
journal78ǡʹ͸ͷͷǦʹ͸͸͹ȋʹͲͲͲȌǤ
͵Ͳ 	ǡ	ǤǡǡǤǡǡǤƬǡǤ
Ǥ

ȗ͵ǤͳǣǤBehavior research 
methods41ǡͳͳͶͻǦͳͳ͸ͲȋʹͲͲͻȌǤ

 
 




